Dr. Robson provides evidence-based leadership for pharmacy, specialty pharmacy, healthcare services, digital innovation and retail merchandising. He is the medical director of the Walgreens Pandemic Response and is leading the development of a healthcare destination that integrates primary care, pharmacy, and ancillary services (labs and digital resources) into the flow of people’s lives. He also leads Walgreens’ development of pharmacogenomics and clinical research. Dr. Robson holds an MBA in healthcare delivery science from Dartmouth.

Dr. Monzon is a molecular pathologist with expertise in clinical genomics, molecular diagnostics and pathology informatics. He was chief medical officer (CMO) at Castle Biosciences and is currently CMO at Universal Diagnostics. He has a strong track record of clinical lab innovation focused on translating novel genomic technologies into medicine. At the University of Pittsburgh, he led the clinical validation study supporting FDA clearance of one of the first gene expression tests using gene expression microarrays (Pathwork Tissue of Origin). Dr. Monzon has directed molecular diagnostics laboratories at Houston Methodist Hospital and at Baylor College of Medicine (BCM), where he oversaw the launch of the first NGS-based clinical cancer exome in the US. At Invitae, he led the oncology team, working closely with the commercial team on business strategy and medical affairs in Latin America.

Dr. Hegde is an adjunct professor of applied biology at Georgia Tech and previously served as executive director of Emory Genetics Laboratory and was professor of genetics and pediatrics at Emory University. Her clinical work focuses on high-throughput strategies for discovery and clinical testing for rare disorders, using next generation sequencing (NGS), robotics, clinical exome and genome sequencing, and oligonucleotide array platforms. Dr. Hegde has over 20 years’ experience in clinical diagnostics, and has extensive knowledge of CLIA, CAP, and NY regulations related to LDTs and NGS. She has served on several FDA panels related to NGS and other molecular technologies. She received a BSc and an MSc from the University of Bombay, and a PhD from the University of Auckland, New Zealand. She completed postdoctoral studies at Baylor College of Medicine.

Dr. Esquivel is a practicing physician-scientist, senior executive, and international business leader with expertise in developing new markets in genomics and precision medicine. As founder and president of ALAMP, he mobilized the regional healthcare community to engage in precision medicine. ALAMP now includes >400 members from nine Latin American countries and holds symposia, provider workshops, and other educational events.